Editas Medicine, Inc. (EDIT) NASDAQ
2.82
-0.52(-15.57%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
2.82
-0.52(-15.57%)
Currency In USD
| Previous Close | 3.34 |
| Open | 3.28 |
| Day High | 3.29 |
| Day Low | 2.81 |
| 52-Week High | 4.54 |
| 52-Week Low | 1.66 |
| Volume | 3.84M |
| Average Volume | 2.03M |
| Market Cap | 276.1M |
| PE | -2.47 |
| EPS | -1.14 |
| Moving Average 50 Days | 2.91 |
| Moving Average 200 Days | 2.67 |
| Change | -0.52 |
Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025
GlobeNewswire Inc.
Nov 03, 2025 2:00 PM GMT
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced a moderated digital poster presentation
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
GlobeNewswire Inc.
Oct 09, 2025 3:01 PM GMT
Preclinical data demonstrates proof-of-concept for EDIT-401 with ≥90% mean LDL-C reduction in non-human primates and mouse modelsCAMBRIDGE, Mass., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing com
Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences
GlobeNewswire Inc.
Oct 06, 2025 1:00 PM GMT
CAMBRIDGE, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced an oral presentation at the upcoming Eu